ESMO Studio Actueel Deel 1

In dit eerste deel van ESMO Studio Actueel blikt Tom van ‘t Hek samen met dr. Britt Suelmann, Sarah Einerhand, dr. Martin Rijlaarsdam en prof. dr. Gabe Sonke terug op de eerste ESMO-dagen. Zij bespreken nieuws op het gebied van blaascarcinoom, niercelcarcinoom, cervixcarcinoom en endometriumcarcinoom, én behandelen we een tumoroverstijgend onderwerp, namelijk de kloof tussen werkzaamheid en effectiviteit.

Bent u geïnteresseerd in een specifiek onderwerp van dit programma? Klik dan rechts in de videospeler voor de hoofdstukindeling.

Bekijk hier de interviews en de andere delen van ESMO Studio Actueel.

De volgende abstracts komen aan bod:

Blaascarcinoom

• 2359O - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
• 2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
• LBA7 - Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial 
• LBA6 - EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)
• LBA103 - ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1

Niercelcarcinoom

• 1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
• LBA87 - Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)

Endometriumcarcinoom

• LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
• LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial
• 740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Cervixcarcinoom

• LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
• LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial